Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Hepatitis B Settlements May Require General Tax Increase: Health Minister Hosokawa
July 18, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- JACDS, JPA to Cooperate Regarding nternet Drug Sales, Unification of Basic Dispensing Fees
July 18, 2011
- Sandoz, Nipro Team Up to Develop, Market Generics
July 18, 2011
- Integration of Nycomed to Accelerate Development of World-class Workforce: Takeda
July 18, 2011
- Korosho Calls For Study on Deregulation of Online OTC Drug Sales in FY2011
July 18, 2011
- Pharmacists Call For Elimination of “No Generics”Option on Prescription Forms: Survey
July 18, 2011
- Problems Can't Be Solved by Meeting Only Once a Year: Mr Matsutani
July 18, 2011
- Regulatory Strategy Consultation to Upgrade Quality of Review, Development: Mr Hirayama of Korosho
July 18, 2011
- Bristol-Myers, AZ Report Breast, Bladder Cancer Findings for Investigational Diabetes Drug
July 18, 2011
- Foreign-affiliated Drug Makers Hire More New Graduates in 2011
July 18, 2011
- Total Review Period for Standard Products Reduced by 4.5 Months to 14.7 Months: PMDA
July 18, 2011
- Positive PII Results for Takeda's TAK-875 Presented at ADA
July 18, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…